LMR Partners LLP Sells 30,000 Shares of Rapport Therapeutics (NASDAQ:RAPP)

LMR Partners LLP reduced its position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 60.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the company's stock after selling 30,000 shares during the quarter. LMR Partners LLP owned approximately 0.05% of Rapport Therapeutics worth $410,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Values First Advisors Inc. acquired a new position in Rapport Therapeutics during the third quarter worth $31,000. SG Americas Securities LLC acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth about $101,000. Sandia Investment Management LP bought a new position in Rapport Therapeutics during the 2nd quarter valued at about $116,000. Davidson Kempner Capital Management LP acquired a new position in Rapport Therapeutics in the second quarter valued at about $229,000. Finally, Squarepoint Ops LLC bought a new stake in Rapport Therapeutics during the second quarter worth about $380,000.

Rapport Therapeutics Trading Down 0.4 %

Shares of NASDAQ RAPP traded down $0.09 during mid-day trading on Wednesday, hitting $22.19. 125,319 shares of the stock were exchanged, compared to its average volume of 157,286. Rapport Therapeutics has a twelve month low of $16.55 and a twelve month high of $29.74. The firm's fifty day moving average price is $22.66.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.